Five new semaglutide trials in Egypt focus on bariatric surgery

Eight GLP-1 developments were tracked on Tuesday, October 6, 2026, and most of them share one theme: what happens when weight comes back after bariatric surgery. One item is a safety recall that requires immediate action. Most of the others are trials, including five new studies in Egypt set to open in October 2026, built specifically around people whose surgery results have faded. If you have had bariatric surgery or take semaglutide for another condition, several of these developments may apply directly to you.

Amneal has recalled one lot of its generic Exenatide Injection USP prefilled pens, lot AP250095A with an expiration date of February 28, 2027, because some pens may contain no medication at all. This is Amneal's generic exenatide, not the brand Byetta. The pens carry NDC 70121-1685-1, manufactured by Amneal Pharmaceuticals in India and distributed by Amneal Pharmaceuticals LLC in Bridgewater, New Jersey. If you use this product, I would suggest checking your pen's lot number right away. If you have that lot, ask your pharmacy for a replacement. An empty pen will not deliver the dose you expect, which could leave a gap in your treatment without warning.

A large international trial, structured as an adaptive platform study and open since 2024, continues to recruit people with chronic kidney disease in Australia, India, New Zealand, Spain and Sri Lanka to test whether semaglutide can slow the damage the disease causes. The trial is testing semaglutide both on its own and in combination with other drugs, which allows researchers to compare several treatment approaches within the same study. This design is meant to produce answers more efficiently than running separate trials for each combination. If you have chronic kidney disease, this trial may be worth discussing with your doctor, since it is open in those five countries and is currently in Phase 3.

A separate trial in Egypt, called RESURGE, is aimed directly at people who lost weight after bariatric surgery and then gained some of it back. The study will test semaglutide at the 2.4 mg weekly dose specifically in this group, rather than in people trying GLP-1 drugs for the first time. It is currently listed as not yet recruiting, with enrollment expected to begin in October 2026. This is a Phase 4 trial, meaning the drug is already approved and the research is focused on how it performs in real-world use after surgery has already been tried once.

Another Phase 4 trial will look at a more complicated situation: patients who had a sleeve gastrectomy, regained weight, and are now having that surgery converted to a Roux-en-Y gastric bypass. Researchers will give semaglutide both before and after the conversion procedure, rather than just afterward. The goal is to see whether adding the drug around the time of a second surgery produces better results than the surgery alone. This trial is also set to open in October 2026 and has not yet begun recruiting participants.

A fifth trial addresses a practical question that comes up once semaglutide treatment ends: whether tapering the dose down slowly works better than stopping it all at once. Researchers will study this in people who were given semaglutide to treat weight regain or a weaker-than-expected result after bariatric surgery, comparing a gradual taper against abrupt discontinuation. The answer could shape how doctors advise patients to come off the drug once a course of treatment following surgery is complete. This trial, like the others, is not yet recruiting and is expected to open in October 2026.

If you use Amneal's generic exenatide pens, the most urgent step is to check for lot AP250095A and ask your pharmacy for a replacement if you have it. For everyone else, these trials represent a shift worth watching: researchers are building studies specifically around what happens after bariatric surgery stops producing the results it once did, rather than treating weight regain as an afterthought. If you have had bariatric surgery and are considering one of these trials, I would suggest talking with your surgeon or a study coordinator about eligibility before enrollment opens. Pay attention to whether a trial is recruiting now or expected to open in October 2026, since timing will affect when you can actually take part.

By Amanda Bonello